(Q37359275)

19 August 2017

1 reference

title

Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? (English)

1 reference

19 August 2017

1 reference

1 reference

3

Patrick A Kupelian

1 reference

19 August 2017

Eric A Klein

1

1 reference

19 August 2017

Jay Ciezki

series ordinal

2

1 reference

19 August 2017

Arul Mahadevan

series ordinal

4

1 reference

19 August 2017

publication date

1 January 2009

1 reference

19 August 2017

1 reference

19 August 2017

volume

27

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

67-71

1 reference

Radical surgery versus radiotherapy for adenocarcinoma of the prostate

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

More on the uro-oncology research group report of radical surgery vs. radiotherapy for adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Prostate Specific Antigen as an Outcome Variable for T1 and T2 Prostate Cancer Treated by Radiation Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Dosimetric comparison of pre-planned and or-planned prostate seed brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

Cancer incidence after localized therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.04.001

10.1016/J.UROLONC.2008.04.001

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference